Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The progression of neoplasms is frequently associated with thromboembolic complications. Coagulation proteins, particularly tissue factor (TF), have been shown to play a role in tumor growth and metastatic dissemination. TFPI is the principal inhibitor of TF-dependent pathway of blood coagulation, but previous studies failed to detect antigenic TFPI in cancer tissue. Recently, a second inhibitor of tissue factor dependent pathway,
TFPI-2
(also known as placental protein 5 [PP5] or matrix-associated serine protease inhibitor [MSPI]), has been described. Information on the presence of
TFPI-2
within the malignant tumor tissue still remains obscure, and thus the aim of this study was to evaluate the expression of
TFPI-2
in loco in several different neoplasms.
TFPI-2
expression was demonstrated by immunohistochemical procedures in neoplastic cells of laryngeal, breast, gastric, colon, pancreatic, renal and
endometrial cancer
, as well as glial neoplasms. The intensity of staining was not uniform, with higher intensity in more differentiated tumors. G3 breast, gastric, endometrial and colon cancer cells revealed populations of cells that were either
TFPI-2
positive or negative. Gastric and renal cancer tissue exhibited the presence of
TFPI-2
in tumor infiltrating macrophages.
TFPI-2
was also observed in normal tissue of the breast, stomach, colon and pancreas. These data demonstrate that the expression of
TFPI-2
diminishes with an increasing degree of malignancy, which may suggest a role for
TFPI-2
in the maintenance of tumor stability and inhibition of the growth of neoplasms.
...
PMID:Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. 1287 37
